

(Atty Dkt. No.: STAN-110CON
USSN: 09/837,446)

inflammation in a mammalian host, the method comprising:

administering an effective amount of a CCR4 antagonist in a dose effective to inhibit said trafficking of systemic memory T cells.

24. The method of claim 23, wherein the site of inflammation is an endothelial cell.
25. The method of claim 24, wherein the endothelial cell is activated.
26. The method of claim 23, wherein the antagonist inhibits the binding of CCR4 to TARC.
27. The method of claim 23, wherein the antagonist inhibits adhesion of the cells to cells at the site of inflammation.
- A1 28. The method of claim 23, wherein the antagonist inhibits chemotaxis of the cells.
29. The method of claim 23, wherein the antagonist is an antibody.
30. The method of claim 29, wherein the antibody is a monoclonal antibody.
31. The method of claim 29, wherein the antibody is humanized.
32. The method of claim 29, wherein the antibody binds to CCR4.
33. The method of claim 23, wherein the site of inflammation is a site of psoriasis.
34. The method of claim 23, wherein the site of inflammation is a site of lichen planus.
35. The method of claim 23, wherein the site of inflammation is a site of atopic dermatitis.
36. The method of claim 23, wherein the site of inflammation is a site of delayed hypersensitivity.

(22)